Hims to Sell Lilly's Zepbound Through Its Telehealth Platform
Hims & Hers Health Inc.'s shares jumped Tuesday after it said it was broadening its weight-loss offerings, adding access to brand name shots like Zepbound after previously focusing on cheaper versions made by compounding pharmacies.
Hims shares gained as much as 14% in New York, their biggest gain since Feb. 19.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 hours ago
- Yahoo
Weight-Loss Medications Less Effective for People in the 'Real World,' New Study Finds
A new study analyzed patients who used GLP-1 medications in a real-world setting Researchers found that participants lost less weight compared to use in clinical trials They believe discontinuation rates are due to high out-of-pocket costs, issues with insurance coverage, side effects and supply shortagesWeight-loss medications like Ozempic and Mounjaro are not as effective in a 'real-world' setting, according to a new study. The study — published June 10 in the Obesity Journal — analyzed nearly 8,000 patients who were classified as having severe obesity. Between 2021 and 2023, they were treated with semaglutide or tirzepatide, injectable GLP-1 medications, in a real-world setting. GLP-1 is short for glucagon-like peptide-1 receptor agonists, which work in the brain to impact satiety. Semaglutide is sold under brand names Ozempic and Wegovy, and tirzepatide is sold under brand names Mounjaro and Zepbound. In a follow-up study, which ended in December 2024, researchers grouped patients who discontinued their obesity medications into those who discontinued early (within 3 months) and late (within 3-12 months). Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. is now available in the Apple App Store! Download it now for the most binge-worthy celeb content, exclusive video clips, astrology updates and more! They found that more than 20% of patients discontinued their medications early and 32% discontinued their medications late. Additionally, more than 80% of patients were on lower maintenance dosages of their medications. After a year of treatment, the average weight loss was 3.6% for those who discontinued their treatment early, compared to 6.8% for those who discontinued their treatment late. Those who continued treatment lost about 12% of their body weight. During clinical trials for the GLP-1s, patients lost about 15% to 20% of their body weight. 'Our findings about the real-world use patterns of these medications and associated clinical outcomes could inform the decisions of healthcare providers and their patients on the role of treatment discontinuation and maintenance dosage in achieving clinically meaningful weight reductions,' Dr. Hamlet Gasoyan, Cleveland Clinic researcher and lead author of the study, said in a statement. The study notes that discontinuation rates during real-world use were higher than those in a clinical trial setting due to high out-of-pocket costs, issues with insurance coverage, side effects and supply shortages. Read the original article on People
Yahoo
a day ago
- Yahoo
Down 12%, Should You Buy the Dip on Eli Lilly?
Eli Lilly's revenue has soared in recent years thanks to its leadership in the weight loss drug market. The company recently released positive phase 3 data from a potential new addition to that portfolio. 10 stocks we like better than Eli Lilly › Eli Lilly (NYSE: LLY) has been a great growth pick for investors over the past few years. The pharma company, thanks to its weight loss drug portfolio, has seen revenue climb in the double digits -- and as a result, the stock has taken off, climbing more than 170% in three years. You may recognize the names of these blockbusters driving Lilly's growth, as they've been widely talked about across the media. Lilly sells tirzepatide, commercialized as Zepbound for weight loss and Mounjaro for type 2 diabetes. Doctors have prescribed either for the weight loss indication, and together, the two drugs generated more than $16 billion in revenue for Lilly last year. On top of this, Lilly has a broad portfolio of drugs targeting a wide range of indications, so this company doesn't rely uniquely on one treatment area -- though the weight loss portfolio has been the focus in recent times due to its performance so far and future prospects. All of this is fantastic, but it has pushed the valuation of this stock higher -- so it resembles that of a tech stock rather than that of a pharmaceutical company. In recent times, though, Lilly has become less expensive, as the stock slipped 12% from a high reached in March. Is Lilly a buy on the dip? Let's find out. So, let's consider what might be ahead for the company's weight loss portfolio. While it may seem as if the growth story is in full bloom right now, there could be a lot more to come down the road -- for two reasons. First, analysts have forecast that the weight loss drug market may reach nearly $100 billion in about five years -- up from about $28 billion today. Second, Lilly's current drugs may represent its very first step in this high-potential market. The company is developing two other candidates that could prove to be even better than current options -- and they're both approaching the finish line. Today, tirzepatide is given in injectable form weekly. The drug, known as a dual GIP/GLP-1 receptor agonist, acts on hormones involved in digestion, and as a result helps regulate appetite and blood sugar levels. The product has been so popular that it was on the market regulator's drug shortage list until Lilly ramped up manufacturing to meet soaring demand. Moving forward, Lilly may offer those aiming to lose weight another even better option: a weight loss drug in pill form. The company's candidate, orforglipron, recently delivered strong efficacy data and a safety profile similar to today's injectables, and Lilly aims to apply for regulatory approval in the weight loss indication by year-end and in the type 2 diabetes indication next year. This potential product could represent significant growth for Lilly because patients may prefer a pill to an injection, and it's easier and cheaper for Lilly to manufacture a pill than medicine in an injection pen format. Lilly also has another weight loss candidate -- retatrutide -- in phase 3 trials, and it acts on not just two but three hormonal pathways, suggesting it may be even more efficacious than current commercialized weight loss drugs. All this means Lilly's weight loss drug-driven growth could be in its early days. And the company has prepared for this, making the biggest-ever pharma manufacturing investment in the U.S. -- this is a commitment of more than $50 billion over the past five years. Of course, Lilly may face some headwinds that could limit the pace of growth. For example, a lack of reimbursement from certain health plans or pricing pressures as rival drugs enter the market represents risks. In fact, these and other concerns prompted Goldman Sachs Research to lower its obesity drug market forecast to $95 billion by 2030 from $130 billion. Still, even considering potential headwinds, Lilly is likely to deliver significant growth from its weight loss drugs in the years to come, especially since it is leading when it comes to innovation -- orforglipron would represent the only weight loss drug of its class in pill format that doesn't come with strict food and water guidelines. So, does this make Lilly a buy today? The stock trades at 37x forward earnings estimates, down from nearly 43x just three months ago. This is expensive for a pharmaceutical company, but Lilly's leadership in the high-growth weight loss market makes it worth this premium. At the same time, like its pharma counterparts, Lilly offers investors the safety of a big pharmaceutical company -- regardless of the economic situation, people need their medicines, and this results in steady revenue for these players. Also, like pharma rivals, Lilly offers investors passive income in the form of dividends. So, the answer to our question, is, yes, Lilly is a buy on the dip, because it gives investors the best of both worlds -- strong growth and safety. And today you can get that on sale. Before you buy stock in Eli Lilly, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Eli Lilly wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $657,871!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $875,479!* Now, it's worth noting Stock Advisor's total average return is 998% — a market-crushing outperformance compared to 174% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Goldman Sachs Group. The Motley Fool has a disclosure policy. Down 12%, Should You Buy the Dip on Eli Lilly? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Miami Herald
a day ago
- Miami Herald
Lilly's experimental obesity drug shows promise in early study
An experimental weight-loss drug from Eli Lilly & Co. helped patients lose weight with few side effects, according to the summary of a small study that suggests the company has another foothold in the obesity market. The drug, called eloralintide, helped some patients lose more than 11% of their body weight in three months, according to an abstract posted Friday ahead of the American Diabetes Association conference in Chicago. The drug is moving to the next stage of development and researchers will present details on dosing and safety at the conference next week. "The data look particularly strong, and should push the program back into investor conversations," Cantor Fitzgerald analyst Prakhar Agrawal wrote in a note to investors. Lilly has shared few details about eloralintide before now, as it's still in the early stages of testing. It's part of a class of drugs that mimic the hormone amylin, which slows digestion and makes people feel full longer. They're thought to be a gentler option for losing weight than currently available injections like Zepbound and Wegovy, which often have side effects like nausea and vomiting. The study enrolled 100 patients who were given different doses of the experimental drug or a placebo for 12 weeks. Weight loss ranged from 2.6% to 11.3%, according to the abstract. Gastrointestinal side effects were relatively minimal, with about 10% of patients experiencing diarrhea and 8% vomiting. Few details were provided, however, including information on risks and benefits based on dose. The promise of drugs that are easier to take than blockbusters like Lilly's Zepbound and its rival Wegovy, from Novo Nordisk A/S, has drawn increasing interest from companies hoping for a piece of pharma's hottest market. In March, Roche Holding AG entered into a $5.3 billion deal to co-develop and commercialize Zealand Pharma A/S' amylin drug, called petrelintide. It is seen as the one to beat in the amylin class, with early trials showing patients lost as much as 8.6% of their body weight in four months, with less nausea than Lilly and Novo's current therapies. AbbVie Inc. agreed to pay as much as $2.2 billion in March for an amylin drug from Danish biotech Gubra A/S, marking its first foray into the obesity market. New York-based startup Metsera Inc. is developing a related compound that may be taken less frequently than weekly shots like Zepbound and Wegovy. Lilly is already a leader in the obesity market, where Zepbound is capturing the majority of new prescriptions. The company has several promising next-generation products in the late stages of development, including a pill called orforglipron and an experimental shot that's thought to be even more effective for weight loss. The company is studying eloralintide alone and in combination with Zepbound - similar to the approach Novo is taking with its next-generation drug CagriSema, which combines an amylin component with semaglutide, the backbone of Wegovy and the diabetes drug Ozempic. Copyright (C) 2025, Tribune Content Agency, LLC. Portions copyrighted by the respective providers.
